Harvard Bioscience, Inc. Share Price
Stocks
HBIO
US4169062043
Advanced Medical Equipment & Technology
|
Market Closed -
Nasdaq
01:30:00 17/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 8.090 USD | -2.65% |
|
-1.82% | +20.96% |
| 07/10 | Harvard Bioscience, Inc. Announces Creation of Scientific Advisory Board | CI |
| 12/08 | Harvard Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 3.68Cr 3.28Cr 3.03Cr 2.76Cr 5.21Cr 349.72Cr 5.3Cr 36Cr 14Cr 182.33Cr 14Cr 14Cr 581.84Cr | P/E 2026 * |
-4.16x | P/E 2027 * | -17.4x |
|---|---|---|---|---|---|
| Enterprise Value | 3.68Cr 3.28Cr 3.03Cr 2.76Cr 5.21Cr 349.72Cr 5.3Cr 36Cr 14Cr 182.33Cr 14Cr 14Cr 581.84Cr | EV / Sales 2026 * |
0.41x | EV / Sales 2027 * | 0.39x |
| Free-Float |
90.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| HBIO | Delayed | |
CBOE
| HBIO | Real-time |
Last Transcript: Harvard Bioscience, Inc.
| 1 day | -2.65% | ||
| 1 week | -1.82% | ||
| Current month | +2.15% | ||
| 1 month | +1.51% | ||
| 3 months | +35.97% | ||
| 6 months | +36.89% | ||
| Current year | +20.96% |
| 1 week | 7.9 |  | 8.53 |
| 1 month | 7.85 | | 8.8 |
| Current year | 4 | | 8.8 |
| 1 year | 3.8 | | 9.4 |
| 3 years | 2.81 | | 55.6 |
| 5 years | 2.81 | | 82.3 |
| 10 years | 2.81 | | 87.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Duke
CEO | Chief Executive Officer | 55 | 28/07/2025 |
Mark Frost
DFI | Director of Finance/CFO | 63 | 12/05/2025 |
Diane Houston
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Katherine Eade
BRD | Director/Board Member | 52 | 24/10/2017 |
John Duke
BRD | Director/Board Member | 55 | 02/06/2025 |
Robert Gagnon
BRD | Director/Board Member | 52 | 16/07/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/03/26 | Free | Chief Executive Officer | 75,000 | 0.1677% | ||
| 20/03/26 | Free | Chief Financial Officer | 30,000 | 0.0671% | ||
| 17/03/26 | Buy | Director | 10,000 | 0.0224% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.65% | -1.82% | +102.25% | -80.74% | 3.68Cr | |
| -0.93% | +4.86% | +28.54% | +41.24% | 26TCr | |
| -1.06% | +4.20% | +8.59% | +8.83% | 16TCr | |
| -0.27% | +0.65% | -1.82% | +55.64% | 15TCr | |
| +0.57% | +3.88% | -54.60% | -11.40% | 6.43TCr | |
| +1.47% | +5.90% | -12.94% | -13.05% | 5.19TCr | |
| -1.70% | +1.63% | +19.20% | +21.51% | 4.99TCr | |
| -0.85% | +4.81% | +6.02% | +46.42% | 5.03TCr | |
| -1.47% | +1.42% | +22.59% | +55.13% | 4.88TCr | |
| -1.62% | +0.73% | +30.48% | +71.24% | 4.29TCr | |
| Average | -0.85% | +3.10% | +14.83% | +19.48% | 8.75TCr | |
| Weighted average by Cap. | -0.69% | +4.13% | +9.01% | +32.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.98Cr 7.99Cr 7.4Cr 6.74Cr 13Cr 852.74Cr 13Cr 89Cr 35Cr 444.59Cr 34Cr 33Cr 1.42TCr | 9.46Cr 8.41Cr 7.79Cr 7.09Cr 13Cr 897.85Cr 14Cr 94Cr 37Cr 468.11Cr 35Cr 35Cr 1.49TCr |
| Net income | -89L -79.19L -73.3L -66.78L -1.26Cr -85Cr -1.28Cr -8.81Cr -3.46Cr -44Cr -3.34Cr -3.27Cr -140.61Cr | -22L -19.57L -18.12L -16.51L -31.1L -21Cr -31.68L -2.18Cr -85.47L -11Cr -82.56L -80.8L -35Cr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | $8.090 | -2.65% | 20,181 |
| 15/26/15 | $8.310 | +1.96% | 16,561 |
| 14/26/14 | $8.150 | -1.45% | 11,623 |
| 13/26/13 | $8.270 | +0.36% | 6,474 |
| 12/26/12 | $8.240 | 0.00% | 8,925 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HBIO Stock
Select your edition
All financial news and data tailored to specific country editions
